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1. Introduction 
Nowadays improvement in overall survival in patients suffered from cancer is observed. It 
is caused by using more effective treatments. The often observed side effect of anti-cancer 
therapy is cardiotoxicity. The decision about further treatment in cancer patients can be 
affected by the risk of development of this complication.  
This chapter presents examples of proven cardiac toxicity associated with oncology 
treatment. It describes cytotoxic drugs used in chemotherapy, new anticancer agents from 
the group of molecular targeted therapy, radiotherapy and supportive treatment in 
oncology.  
Drug-induced cardiomyopathy, which is a consequence of oncological treatment may be 
asymptomatic or present with acute or chronic heart failure, myocardial infarction, 
arrhythmia or sudden cardiac death. [1] 
Drug-induced toxicity can be divided depending on the time of onset:  
 acute: namely, that appeared in the course of cancer therapy,  
 chronic: that is to say, that occurred within 12 months of completion of oncological 
treatment and  
 chronic delayed: that is appearing 5 years after the end of treatment. [1] 
2. Cytostatics with confirmed myocardial toxicity: Anthracycline antibiotics, 
nitrogen mustard-derivatives (cyclophosphamide and ifosfamide),  
5-fluorouracil and mitomycin C. [1,2]  
2.1 Anthracycline antibiotics 
Anthracycline antibiotics are compounds isolated from fungi Streptomyces percetus and 
Streptomyces caesius.  
2.1.1 The mechanism of anticancer action of anthracyclines 
 incorporation to the structure of DNA, leading directly to inhibit transcription, protein 
production and replication problems,  
 formation of additional abnormal bonds between nitrogen bases of DNA strands, which 
causes disruption of DNA and RNA synthesis and impaired DNA repair mechanisms,  
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 interference in the process of separating the strands of DNA and helicase activity, 
inhibition of key enzymes in the synthesis of DNA topoisomerase I and II,  
 formation of free radicals that damage DNA, causing lipid peroxidation and 
accumulation of proapoptotic ceramide,  
 induction of apoptosis via activation of p53. [3,4,5]  
2.1.2 Clinical application of anthracyclines 
Due to antitumor activity of anthracycline antibiotics they are incorporated into many 
therapeutic regimens in both solid tumors and hematological cancers. For example, 
doxorubicin is used to treat breast cancer, lymphoma, Ewing sarcoma, small cell lung cancer 
and soft tissue sarcomas. Daunorubicin is used primarily to treat acute myeloid and 
lymphoblastic leukemias. [6]  
The cardiotoxicity of anthracycline antibiotics has been already documented in the seventies 
and affects all currently used anthracyclines [2]:  
 doxorubicin,  
 daunorubicin,  
 epirubicin,  
 esorubicin,  
 aklarubicin,  
 idarubicin  
 and mitoxantrone, derivative-anthracycline. 
The newer generation of antibiotics are derivatives of liposomal anthracycline doxorubicin, 
which are characterized by lower cardiotoxicity compared to their predecessors. [1,2]  
2.1.3 Risk factors for cardiotoxicity after treatment with anthracyclines 
Toxicity of anthracycline antibiotics depends on the dose. Most published reports showed 
that, the possibility of permanent myocardial damage is significantly increased beyond the 
cumulative dose of anthracyclines. 
The cumulative doses significantly increasing the risk of permanent damage of heart 
muscule are as follow: 
 doksorubicin-550mg/m2 (450 mg/m2 when radiotherapy was used or when  
other risk factors of cardiotoxicity are present), 
 daunorubicin-600mg/m2,  
 epirubicin-1000 mg/m2,  
 esorubicin-1900 mg/m2,  
 aklarubicin-2000-3000 mg/m2,  
 mitoxantrone-160 mg/m2. [2]  
Other risk factors of cardiotoxicity associated with anthracycline antibiotics treatment 
include:  
 individual susceptibility of the patient,  
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 genetic polymorphism associated with drug transport and metabolism of free radicals,  
 age (over 65 years and under 4 years),  
 black race,  
 Down syndrome,  
 prior mediastinal irradiation of ionizing radiation dose > 20Gy,  
 previous cytotoxic therapy with potentially cardiotoxic drugs,  
 pre-existing heart disease (valvular, ischemic origin, etc.),  
 hypertension,  
 diabetes,  
 liver disease, [1,2] 
 higher risk for chronic heart failure is observed in women,  
 late coronary events are more common in men. [7] 
2.1.4 Mechanism of cardiotoxicity action of anthracyclines 
Mechanisms of anthracyclines cardiotoxicity with the pathogenesis of cardiomyopathy and 
heart failure are not fully explained.  
One hypothesis assumes that the cardiotoxic effect of anthracyclines is a consequence of 
damage of mitochondria by these drugs. They bind to cardiolipin forming part of the inner 
mitochondrial membrane. This results in unbalanced electron transport in the respiratory 
chain, leading to depletion of ATP and phosphocreatine stores resulting in a decrease in 
myocardial contractility. Doxorubicin-cardiolipin complex also causes the formation of free 
hydroxyl radicals and hydrogen peroxide, which contributes to further damage to cell 
membranes and DNA. [2] The biopsy of the myocardium after therapy with anthracylines 
revealed myocyte vacualization, reduce  amount of myofibrils, an increased number of 
lysosomes and mitochondria swelling. [8] Billigham scale is used in order to evaluate the 
histological severity. [9]  
At present the most intensive examination of factors involved in the pathogenesis of 
anthracycline cardiomyopathy is cardiomyocyte apoptosis. Anthracyclines induce myocyte 
death through changes in protein expression of Bax (a protein with Bcl-2 family, cytochrome 
c release through mitochondrial pore opening) and Bcl-Xl (a protein with Bcl-2 family block 
cytochrome c release). [10,11]  
The role of iron ions is significant as well. Iron is necessary for the conversion of O2-and 
H2O2 into the highly reactive hydroxyl radical (OH), and other toxic compounds. They can 
cause death of cardiomyocytes. It is also believed that the anthracycline antibiotics disturb 
cellular iron homeostasis in cardiomyocytes. It is plausible that change in the dynamics of 
release and storage of iron ions in the intracellular resources contribute to the death of heart 
muscle cells. In addition, it is believed that anthracyclines reduce iron release from ferritin, 
thus affect important metabolic processes dependent on iron. Iron is essential for DNA 
synthesis and cytochromes. However, accumulation of iron in ferritin is a protective 
mechanism against apoptosis by slowing the reaction of free radicals. [12,13]  
Another possible mechanism of anthracyclines cardiotoxicity is the influence of 
anthracyclines on the calcium homeostasis. Before leading to apoptosis, oxidative stress can 
induce mitochondrial permeability transition with alterations in mitochondrial calcium 
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transport. Changes in calcium transport can lead to tissue injury, cell killing and impaired 
cardiac contraction. In vitro doxorubicin treatment caused an irreversible decrease in 
mitochondrial calcium loading capacity. Moreover, anthracyclines can stimulate the release 
of calcium from isolated cardiac and skeletal muscle sarcoplasmic reticulum vesicles. This is 
strengthened by the observation of Rossi et al. who found a protective effect of the calcium 
blocking agent verapamil on doxorubicin induced cardiotoxicity in rats. This effect would 
be due to the calcium blocking capacities of verapamil inhibiting the intracellular calcium 
overload and antagonizing the effect of doxorubicin on mitochondria. However, others have 
demonstrated an increase in cardiotoxicity when doxorubicin was given in combination 
with verapamil. Different mechanisms for this effect are postulated. One is based on the 
capacity of verapamil to inhibit the function of P-glycoprotein and increase intracellular 
cytotoxic drug concentrations. This may be useful in overcoming resistance to 
chemotherapeutic drugs in cancer cells, but it could also lead to toxic effects in normal 
structures such as cardiac cells. Some studies showed in vitro increased doxorubicin 
accumulation in rat cardiomyocytes when incubated with a combination of verapamil and 
doxorubicin. Akimoto et al did not show an increased cellular anthracycline uptake but they 
found additive cardiotoxicity by verapamil due to its selective inhibition of cardiac actin 
gene expression, a similar effect which was demonstrated before with doxorubicin alone. 
The exact role of the changing capacities of doxorubicin on calcium regulation and its 
implications for cardiotoxicity remains to be elucidated. [2]  
Recently, clinical trials evaluated the effect of anthracyclines on dysfunction of cardiac stem 
cells. These are undifferentiated cells, who renews themselves and differentiates into cardiac 
muscle cells and coronary vessels both in vitro and in vivo. Cardiac stem cells resulting in 
the surface receptor c-kit have been identified in the adult mammalian heart muscle. There 
is the evidence that the loss of cardiac stem cells with impaired production of daughter cells 
may be responsible for the development of anthracycline cardiomyopathy. Moreover it has 
been found that stem cells show efficacy in the treatment of experimentally induced heart 
failure. [14,15,16] 
Other potential etiologies of development of anthracycline cardiomyopathy, reported in the 
literature are:  
 effect of anthracyclines on the enzymatic antioxidant system cells, via reducition of the 
activity of glutathione peroxidase (GS-PX1) and the amount of copper-zinc superoxide 
dismutase (CuZnSOD) in cardiomyocytes,  
 membrane lipid peroxidation,  
 disruption of titin* (protein associated with myosin, and which is incorporated into the 
structure of sarcomeric),  
                                                                          
* Titin, also known as connectin, is a protein that in humans is encoded by the TTN gene. Titin is a giant 
protein that functions as a molecular spring which is responsible for the passive elasticity of muscle. It is 
composed of 244 individually folded protein domains connected by unstructured peptide sequences. 
These domains unfold when the protein is stretched and refold when the tension is removed. Titin is 
important in the contraction of striated muscle tissues. It connects the Z line to the M line in the 
sarcomere. The protein contributes to force transmission at the Z line and resting tension in the I band 
region. It limits the range of motion of the sarcomere in tension, thus contributing to the passive 
stiffness of muscle. 
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 abnormal calcium homeostasis and cardiac contractility, reduction in expression of 
contractile proteins and proteins regulating intracellular calcium movement, 
 inactivation of mitochondrial creatine kinase and abnormal structure of dystrophin. 
[17,18,19]  
Acute cardiotoxicity associated with anthracyclines may occur after either first or initial few 
infusions of drug. It is not dose depend and presents as  sinus tachycardia. It may result in 
myocarditis, with or without pericarditis.  
The ECG changes include: 
 voltage decrease.  
 widening of QRS complexes.  
 small R wave progression [anterior wall of heart]. 
 nonspecific T wave changes. 
Acute cardiotoxicity associated with anthracyclines despite its the transient nature can cause 
life-threatening complications such as myocardial infarction, pulmonary edema, 
hypotension and serious arrhythmias. [20]  
Chronic anthracycline cardiotoxicity occurs during the first year after treatment [10% of 
patients treated with anthracyclines]. It is dose-dependent. Most commonly it is manifested 
as exacerbation of heart failure, decrease in ejection fraction, cardiac arrhythmias, and 
development of dilated cardiomyopathy. A history of treatment with anthracyclines may be 
associated with long-term risk of cardiac complications in both children and adults. [20] 
Mitoxantrone is a derivative of anthracycline-like structure similar to doxorubicin and 
contributes to the occurrence of left ventricular dysfunction. It has been used in the 
induction of remission in acute myeloid leukemia, in breast cancer and ovarian cancer 
resistant to chemotherapy as well as prostate cancer resistant to hormonotherapy. In the 
assessment of 80 patients treated with mitoxantrone, clinical congestive heart failure (CHF) 
was diagnosed in 1.5% of them. The risk of cardiac complications increases after the total 
dose of 160 mg/m2. Reduction of left ventricular EF [LVEF] was observed in patients with 
prior history of diseases of the cardiovascular system and with previous exposure to 
anthracyclines. [21] 
Mechanism of cardiotoxicity action of anthracyclines is shown in Table nr 1. 
2.2 Cardiotoxicity of taxanes 
Cardiac complications may be caused by another group of cytostatic drugs used in 
oncology- the taxanes.  
2.2.1 Mechanism of antitumor action of taxanes 
The mechanism of antitumor action of this relatively new group of cytostatics are: 
 Stabilization of microtubules, causing cell cycle blockage at the stage of mitosis.  
 In addition, docetaxel can induce apoptosis by blocking the antiapoptopic action of 
BCL-2 gene, and by influencing the activation of the p53 gene.  
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At the level of 
myocytes 
 apoptosis of cardiomyocytes as a result of changes in protein 
expression of Bcl-2,  
 mitochondrial damage,  
 decreasing the activity of glutathione peroxidase (GSH-PX1) and 
the amount of copper-zinc superoxide dismutase (CuZnSOD),  
 abnormal cellular iron homeostasis in cardiomyocytes,  
 direct DNA damage of cardiomyocytes, membrane lipid 
peroxidation, disruption of titin, disturbances of calcium 
homeostasis and cardiac contractility, reduced expression of 
contractile proteins and proteins regulating intracellular calcium 
movement, inactivation of mitochondrial creatine kinase and 
abnormal structure of dystrophin. 
At the level of cardiac 
stem cells (SKM) 
 induction of apoptosis and inhibition of proliferation of SKM through 
increased oxidative DNA damage and telomere shortening. 
Table 1. Mechanisms of cardiotoxicity action of anthracyclines 
2.2.2 Clinical application of taxanes 
Taxanes are used primarily in chemotherapy of solid tumors, including lung cancer, 
hormone-refractory prostate cancer, bladder cancer, stomach cancer, breast cancer or 
ovarian cancer. [22]  
2.2.3 Risk factors for cardiotoxicity after treatment with taxanes 
Cardiac risk factors included were age, hypertension, diabetes and prior radiotherapy to the 
chest wall. [2,22,23]  
Docetaxel shows no increase in cardiac toxicity when combined with doxorubicin. This is in 
line with the observation that a pharmacokinetic interaction with doxorubicin as described 
for paclitaxel has not been observed. [2,22]  
2.2.4 Mechanism of cardiotoxicity of taxanes 
During administration of paclitaxel, whether or not combined with cisplatin, various cardiac 
disturbances are reported like brady- and tachyarrhythmias, atrioventricular and bundle 
branch blocks and cardiac ischemia. Hypotension is also reported, probably as a result of a 
hypersensitivity reaction. When evaluating three phase I and one phase II studies performed 
at the John Hopkins Institute it appeared that 5% (n = 7) of the patients showed overt 
cardiac disturbances as ventricular tachycardia and atrioventricular conduction 
abnormalities. Asymptomatic bradycardia occurred in 29% of patients receiving maximal 
tolerable doses (110-250 mg/m2) of paclitaxel in the phase II study. These disturbances did 
not lead to clinical symptoms. The abnormalities usually started several hours following the 
initiation of paclitaxel therapy and resolved after discontinuation. This evident time 
relationship and the fact that most patients had no cardiac risk factors supports the 
assumption of causality between paclitaxel and the observed cardiac rhythm disturbances. 
[2,22,23]  
Another concern with the use of taxoids has been the development of congestive heart 
failure in patients treated with a combination of doxorubicin and taxoids. The cardiotoxicity 
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associated with taxoids seems to be mild in most cases. However, in clinical trials patients 
with prior history of cardiac disturbances were often excluded. Therefore, the rate of 
cardiotoxicity in this group of patients is difficult to estimate. Study in patients with major 
cardiac risk factors revealed that paclitaxel could be safely administered as single therapy or 
in combination with a platinum agent such as cisplatin or carboplatin. Cardiac risk factors 
included unstable angina, severe coronary artery disease, congestive heart failure and atrial 
fibrillation. [2,22,23]  
Paclitaxel is formulated in a cremophor EL vehicle to enhance the drug solubility and it is 
suggested that the vehicle and not the cytotoxic drug itself is responsible for the cardiac 
disturbances. However, the cardiac rhythm disturbances are not reported with use of other 
drugs containing cremophor EL such as cyclosporin. The possible mechanism by which 
cremophor EL would cause cardiotoxicity is massive histamine release. Indeed, stimulation 
of histamine receptors in cardiac tissue in animal studies has resulted in conduction 
disturbances and arrhythmias. An alternative explanation for paclitaxel induced 
cardiotoxicity could be the induction of cardiac muscle damage by affecting subcellular 
organelles. [2] 
Enhanced cardiac toxicity has been found in combined therapy of paclitaxel and doxorubicin. 
At doses of doxorubicin exceeding 380 mg/m2, the toxicity increased in combination therapy 
compared to doxorubicin single therapy. A pharmacokinetic interaction appears to be 
responsible for this effect as paclitaxel has been found to decrease doxorubicin hepatic 
elimination and lead to increased plasma concentrations of doxorubicin. This effect depends 
on the interval and sequence of drug administration as well as the duration of the paclitaxel 
infusion. [2,22] 
A similar effect has been shown for epirubicin. Baldini et al. [23] evaluate cardiac safety of 
two different schedules of epirubicin and paclitaxel in advanced breast cancer. Patients were 
enrolled into a multicenter randomized phase III trial. They received epirubicin 90 mg/m2 
plus paclitaxel 200 mg/m2 (3-h infusion) on day 1 every 3 weeks for eight courses (arm A), 
or epirubicin 120 mg/m2 on day 1 every 3 weeks for four courses followed by four courses 
of paclitaxel 250 mg/m2 on day 1 every 3 weeks (arm B). Baseline median left ventricular 
ejection fraction was 60% in arm A and 65% in arm B; after four courses, figures were 57 and 
60%, respectively. After eight courses, the median left ventricular ejection fraction in arm A 
declined to 50% while no further reduction was detected in arm B by adding four courses of 
high-dose paclitaxel. Seven episodes of congestive heart failure were observed during 
treatment in arm A. The risk of congestive heart failure or impairment in the cardiac 
function correlated only with the cumulative dose of epirubicin. No impact on cardiotoxicity 
can be attributed to high-dose paclitaxel. [23]  
2.3 Cardiotoxicity of nitrogen mustard derivatives of cyclophosphamide [CTX] and 
ifosfamide [IFO] 
2.3.1 Cyclophosphamide 
2.3.1.1 Mechanism of antitumor action of cyclophosphamide 
These drugs are alkylating agents. Their biological active metabolities are responsible for 
their action. Cyclophosphamide and ifosfamide are alkylating oxazaphosphorine agents that 
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need to be metabolized in vivo in the liver to form the active cytotoxic agent phosphoramide 
mustard. They contain many chloroethyl groups and therefore may create cross-binding of 
the DNA chain, causing damage that is difficult to repair. [22]  
2.3.1.2 Clinical application of cyclophosphamide 
Cyclophosphamide has a very wide range of indications:  
 acute myeloid leukemia,  
 acute lymphoblastic leukemia,  
 chronic lymphocytic leukemia,  
 Hodgkin, non-Hodgkin lymphomas,  
 lung, breast, ovarian and bladder cancers, 
 sarcomas, 
 retinoblastoma. 
2.3.1.3 Risk factors for cardiotoxicity after treatment with cyclophosphamide 
Cardiotoxicity of this drug depends on its dose. Described complications of the 
cardiovascular system occur after administration of 120 to 200 mg/kg of cyclophosphamide. 
[24] Some sources indicate that cardiotoxicity of cyclophosphamide may be present in 3% of 
patients who received a dose of less than 1.55 g/m2/daily and in 25% who received 
cyclophosphamide at a daily dose greater than 1.55 g/m2/daily. [25] 
2.3.1.4 Mechanism of cardiotoxicity of  cyclophosphamide 
Cardiac complications observed in patients treated with CTX were as follows:  
 ECG abnormalities in the form of low-voltage QRS wave,  
 progressive heart failure,  
 myocarditis or pericarditis which sometimes lead to cardiac tamponade requiring 
urgent pericardiocentesis.  
In 90% of patients with confirmed adverse effect of cyclophosphamide on the heart muscle, 
there were no clinical signs of cardiac toxicity of this drug. In these cases, ones observed 
mild pericarditis, and slight changes in the ECG that did not require treatment and resolved 
spontaneously without leaving any complications. They were ST-segment abnormalities and 
supraventricular arrhythmias. [25-27] The Harvard Medical School studied the 
cardiotoxicity of cyclophosphamide, depending on the dose in the preparatory regimen 
before bone marrow transplantation. Cyclophosphamide (CTX) cardiotoxicity may be a 
lethal complication of bone marrow transplantation. Previous echocardiographic 
studies have reported that left ventricular dysfunction due to CTX occurs in over 
50% of patients undergoing transplantation. To evaluate the cardiotoxicity of new dosing 
protocols that included twice-daily rather than once-daily CTX, 44 bone marrow 
transplantation patients were prospectively evaluated with serial ECGs and 
echocardiograms. Twenty-six patients received a once-daily lower-dose protocol (mean total 
87 +/- 11 mg/kg), and 18 patients received a twice-daily higher-dose (mean total 174 +/- 34 
mg/kg) CTX regimen. In the higher-dose CTX group, significant reductions in summed 
ECG voltage (-20%) (P less than 0.01) and increases in left ventricular mass index (LVMI) 
(+10%) (P less than 0.05) were detected in the first week following therapy. These changes 
resolved by the third week following CTX and were significantly greater than the changes 
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noted in the lower-dose group. However, LVEF did not change significantly in either group. 
Five patients developed clinical cardiotoxicity (four- pericarditis; one- congestive heart 
failure); four of the five patients were in the higher-dose group (P = 0.14). Only a prior 
history of congestive heart failure or a baseline EF less than 50% was an independent 
correlate of clinical cardiotoxicity (P less than 0.05). Thus, dose-dependent cardiotoxicity 
following the use of CTX for bone marrow transplantation presents as reversible decreases 
in ECG voltage and increases in left ventricular mass. This likely reflects myocardial edema 
or hemorrhage. However, systolic dysfunction is much less common with these new twice- 
daily dosing regimens when compared with earlier studies of high-dose once-daily CTX.  
It has been proven that the cardiotoxicity of cyclophosphamide is a result of its biologically 
active metabolites such as 4-hydroxy cyclophosphamide (HCY), o-carboxyetyl-nitrogen 
mustard (CEPM), deschloroetyl-cyclophosphamide (DCCY), 4-keto-cyclophosphamide 
(KetoCY) and hydroxypropyl nitrogen-mustard (HPPM). [21,29] Endothelial damage by 
toxic metabolites of cyclophosphamide results in extravasation of blood and damage to the 
vessel wall myocytes resulting in intravascular hematoma with subsequent swelling. 
Symptoms of congestive heart failure usually appear within two weeks after drug 
administration. In patients in whom it is rapid, it can lead to death within a few weeks. 
There is evidence that the severity of the toxicity of cyclophosphamide depends on the 
personal attributes associated with the intensity of metabolism of this drug. [21] 
2.3.2 Ifosfamide 
Ifosfamide (IFO) is a structural isomer of cyclophosphamide. 
2.3.2.1 Mechanism of antitumor action of ifosfamide 
Mechanism of action this drug is the same like cyklophosphamide. 
2.3.2.2 Clinical application of ifosfamide 
This cytostatic is used to treat lung cancer, germ cell tumors, sarcomas and lymphomas, 
may also lead to cardiac complications.            
2.3.2.3 Risk factors for cardiotoxicity after treatment with ifosfamide 
The risk of congestive heart failure depends on the dose ifosfamide and increases from 8% 
to 67% at doses ranging from 10 g/m2 to 18 g/m2. An additional risk factor in these cases is 
the development of renal failure with subsequent overload the body's fluids. 
2.3.2.4 Mechanism of cardiotoxicity of  ifosfamide 
In 15% of patients receiving a dose of this cytostatic up to 10g /m2 may experience the 
following variations in the ECG:  
 supraventricular tachycardia,  
 changes in ST-T.  
The development of congestive heart failure (from mild stagnation in the circulation to a 
cardiogenic shock of lesser severity) occurs 6 to 23 days after starting therapy, with 
improvement within 4 to 7 days after discontinuation of cytostatic and appropriate 
treatment. Usually, it is fully reversible. Cardiac tamponade or pericardial effusion is 
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extremely rare. There were reports of various types of arrhythmias after various doses of 
ifosfamide:  
 extrasystoles supraventricular or ventricular,  
 supraventricular tachycardia,  
 atrial fibrillation, 
 atrial flutter,  
 acute ventricular arrhythmias.  
In addition, there were changes in the passage from the ST-T ECG and QRS voltage 
reduction. In a study of patients treated with fractionated doses of ifosfamide (doses ranging 
from 6.5 to 10 g/m2) 15% of them developed symptoms of acute cardiac toxicity in the form 
of supraventricular arrhythmias and changes in ST-T. The symptoms were reversible after 
discontinuation of treatment. In one patient re-use of ifosfamide led to the development of 
arrhythmias resistant to treatment. [30-34] 
The possible causes of cardiac complications associated with cyclophosphamide and 
ifosfamide are electrolyte imbalance. The development of severe hypokalemia was 
described in four patients treated with ifosfamide with mesna supply. Three patients 
received ifosfamide at a dose of 5g /m2, and one at a dose of 4g /m2. One patient was 
treated with ifosfamide + mesna only, others also received mitoxantrone plus etoposide or 
doxorubicin and vindesine, or methotrexate and etoposide. In none of these patients other 
causes of hypokaliemia were found. Hypokaliemia appeared between 2 and 12 days after 
application of ifosfamide with mesna. One death was observed due to cardiac arrest in a 
patient with a potassium level of 2.2 mEq/l. In the remaining patients, the lowest potassium 
levels ranged from 1.7 to 2.6 mEq/l. [35-37]  
Mechanism of cardiotoxicity action of nitrogen mustard derivatives is showen in Table nr 2. 
 
 endothelial damage by toxic metabolites for example: 4-hydroxy cyclophosphamide 
(HCY), o-carboxyetyl-nitrogen mustard (CEPM), deschloroetyl-cyclophosphamide 
(DCCY), 4-keto-cyclophosphamide (KetoCY) and hydroxypropyl-nitrogen mustard 
(HPPM), 
 electrolyte disturbances including hypokalemia 
Table 2. Mechanisms of cardiotoxicity action of cyclophosphamide and ifosfamide 
2.4 Cardiotoxicity of 5-fluorouracil [5-Fu] 
Another chemotherapeutic agents with potentially cardiotoxic action are 5-fluorouracil (5-
Fu) and its prodrug capecitabine-(4-pentoksykarbonylo-5-deoxy-5-fluorocytydyna).  
2.4.1 Mechanism of antitumor action of 5-fluorouracil and capecitabine 
The mechanism of antitumor action of 5-Fu is the inhibition of DNA synthesis by the active 
metabolite - phosphodeoksyrybonucleotide (FdUMP). In addition, 5-Fu forms additional 
metabolite- (5-FUTP), which can be incorporated into RNA. Thus it blocks the processing of 
RNA and its function. 
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2.4.2 Clinical application of 5-Fu and capecitabine 
They are the main cytostatics used in the treatment of epithelial cancers, especially: breast, 
head, neck and gastrointestinal tract. [38] 
2.4.3 Risk factors for cardiotoxicity after treatment with 5-Fu and capecitabine 
The incidence of 5-Fu cardiotoxicity is 7.6% with mortality ranging between 2.2% and 13%. 
[38] Cardiac toxicity of 5-fluorouracil is dose-dependent. A cumulative dose threshold for 
severe heart effects has been calculated between 1.5 and 7g. [39] The risk of cardiac ischemia 
appears to vary ranging from 1-68% in the patients treated with high-dose infusions of 5-
fluorouracil. [40] Cardiac complications after administration of a bolus occur with a 
frequency of 1.6-3%, while after 4-5 days of continuous infusions at a frequency of 7.6-15%. 
2.4.4 Mechanism of 5-fluorouracil cardiotoxicity 
The most often cardiac symptoms are: 
 chest pain,  
 ST-T wale changes,  
 arrhytmias (for example atria fibrylattion),  
 asymptomatic bradycardia,  
 hypotension,  
 cardiogenic shocks,  
 cardiac failure,  
 acute coronary syndrome.  
But most common finding is reversible ST-T wave changes. [41] Fidan et al. [42] described a 
46-year-old patient with stomach cancer, in whom the administration of 5-Fu in the bolus as 
the adjuvant chemoradiotherapy attack of ventricular fibrillation occurred. It was 
accompanied by a decrease in EF to 40%. This complication is extremely rare after 
administration of 5-Fu in the bolus. It has been proved that the administration of the drug in 
the form of short-term injection is safer than continuous infusions. [42] 
The literature describes several potential mechanisms of toxicity of 5-Fu on the 
cardiovascular system. Many authors claim that the basic mechanism is due to coronary 
artery spasm. Ischemia could be because of  direct tonic effect on the vascular endothelium 
involving NO synthase, which leads to coronary vasospasm. The other mechanism of 
vasospasm endothelial vasoconstriction is via protein kinase C. The hypothesis that 
endothelin-1 (ET1) release could be involved in 5-Fu cardiotoxicity has never been 
substantiated. 5-Fu can also damage endothelium, causing thrombus formation and 
vascular endothelial release of vasoactive substances. A reduction of antioxidant defense 
capacities in myocardial tissues and modulation of the immune response are other potential 
causes of 5-Fu cardiotoxicity. The administration of 400 mg/kg/day of 5-Fu to guinea-pigs 
reduced the activity of the cardiac enzymes: superoxide dismutase and glutathione 
peroxidase. Concomitantly there was an increase in the activity of catalases and 
malondialdehyde concentrations. Interestingly, an increase in malondialdehyde 
concentrations is consistently observed in myocardial ischemia and this increase is 
prevented or reversed by calcium inhibitors. A proliferation of the sarcoplasmic reticulum 
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with vacuolizations similar to that occurring with anthracyclines was also reproted with 5-
Fu. [38,43] According to Labianca et al.,[44] the global incidence of heart lesions associated 
with 5-Fu is higher in patients with a cardiac history in comparison to patients with no 
cardiac history (4.5 versus 1.1%). [44] The risk of 5-Fu cardiotoxicity was increased in 5-Fu-
treated patients receiving mediastinal radiotherapy. [45] However Tsibiribi et al. [43] 
described cardiac complications in 16 out of 1350 patients treated with 5-Fu with a negative 
history of diseases of the cardiovascular system. Ten patients complained of angina pectoris. 
Two were asymptomatic, but had electrocardiographic changes indicative of myocardial 
ischemia. Three patients had clinical symptoms without EKG changes. Heart failure was 
observed in one patient. [43]  
2.4.5 Mechanism of cardiotoxicity of capecitabine 
While cardiac events associated with the use of 5-Fu are a well known side effect, 
capecitabine-induced cardiotoxicity has been only rarely reported. Capecitabine is an orally 
active prodrug of 5-Fu and breast cancer and colon cancer exhibits antitumor efficacy 
comparable to 5-Fu. Capecitabine is converted to the active 5-Fu by the action of a series of 
enzymes. One of these enzymes, thymidine phosphorylase (TP), has higher concentrations 
in tumor tissue than in normal tissue. This suggests that the activation occurs preferentially 
in tumor tissue, providing a favorable ratio for toxicity and radiosensitization. [46] In a 
retrospective analysis performed on studies of patients unergoing chemotherapy for 
metastatic breast and colon cancer, the incidence of cardiotoxicity with capecitabine was 
found to be comparable to that of 5-Fu. [47] Wijesinghe et al [48] reported an acute coronary 
syndrome in a patient with no history of cardiovascular disease who had been on 
capecitabine for only 2 days. [48] Kosmas et al documented myocardial infarction, 
electrocardiographic abnormalities, and ventricular extrasystoles in patients on capecitabine. 
[49] Furthermore, Goldsmith et al recently reported exercise-induced global myocardial 
ischemia with an ejection fraction of 36% in a patient with normal coronary arteries and 
resting left ventricular function who was on capecitabine for recurrent breast cancer. [50] 
For the first time cardiac arrhythmia in the form of symptomatic bradycardia described Ang 
C et al. [51] Capecitabine should be considered a drug with cardiotoxic potential even in the 
absence of prior cardiac history. It is believed that 5-Fu or its metabolites were responsible 
for cardiotoxicity after capecitabine administration. Coronary artery vasospasm, direct 
toxicity to the myocardium, thrombogenic effects and autoimmune phenomena have been 
proposed as plausible mechanisms. [52]  
The mechanisms of cardiotoxicity of 5-Fu and capecitabine is shown in Table nr 3. 
 
5-fluorouracil 
coronary artery vasospasm, 
modulation of immune response,  
direct myocardial injury, 
capecitabine 
coronary artery vasospasm,  
direct toxicity to the myocardium,  
thrombogenic effects, 
autoimmune phenomena, 
Table 3. The mechanisms of cardiotoxicity of 5-Fluorouracil and capecitabine 
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2.5 Cardiotoxicity of mitomycin C 
There are reports of potentially cardiotoxic activity of mitomycin C. It is a antibiotic with 
antitumor cytotoxic activity. It is used in multi-drug regimens chemotherapy in the therapy 
of: stomach, colon, pancreatic, small cell lung, breast, cervical, advanced endometrial and 
squamous cell cancers of head and neck. [2]  
2.6 Cardiotoxicity of cisplatin  
2.6.1 Mechanism of antitumor action of cisplatin 
Its effect is to create cross-linkages between adjacent strands of DNA and within the same 
thread. The formation of these cross-linkages prevents DNA replication and cell division. 
Also exerts influence on the metabolic functions of starting the process of cell apoptosis. 
2.6.2 Clinical application of cisplatin 
Cisplatin is a platinum substance and used in the treatment of many tumors (i.e. testicular 
cancer).  
2.6.3 Mechanism of cardiotoxicity of cisplatin 
Several cases of acute myocardial infarction after cisplatin therapy are reported. In a 
retrospective study 87 long term survivors of metastatic testicular cancer treated with 
cisplatin were evaluated for the occurrence of cardiovascular events. A significantly increase 
in cardiac events as well as an unfavorable cardiovascular risk profile were observed. [2]   
Several factors have been suggested to be involved like vascular damage, alterations in 
platelet aggregation and hypomagnesemia. In experiments on human platelets cisplatin was 
able to trigger platelet aggregation and/or enhance thromboxane formation by platelets. 
Activation of an arachidonic pathway in platelets by cisplatin seemed to be involved. 
Raynaud phenomenon has been described in patients receiving cisplatin-based therapy. [2]  
3. Cardiotoxicity of antineoplastic agents belonging to the so-called 
molecular targeted therapy 
Molecular targeted therapy plays an increasingly important role in cancer therapy. This 
kind of treatment is also at risk of complications development including cardiac events. The 
most common symptoms associated with cardiac toxicity of molecular targeted therapy 
include hypertension, thromboembolic complications and dilated cardiomyopathy. Despite 
these symptoms treatment is better tolerated compared to other cytostatics. Most of the 
complications are reversible and respond to symptomatic treatment. Due to the fact that 
some of these drugs are used in combination with chemotherapy, reported side effects are 
the result of overlapping toxicities. Due to the relatively short experience with this type of 
therapy we cannot answer the question about the consequences of targeted therapy. [53]  
This group of drugs of proven cardiac toxicity can be divided into: 
 small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, imatinib, lapatinib, 
dasatinib), 
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 proteasome inhibitors (bortezomib), 
 monoclonal antibodies directed against the receptor or tyrosine kinase ligands 
(trastuzumab, bevacizumab). [54] 
3.1 Small molecule tyrosine kinase inhibitors  
This group of drugs bind to the part of the receptor complex, which is a tyrosine kinase. 
They are transmembrane proteins whose extracellular part acts as a both  receptor and 
associated ligands at the same time [for example vascular endothelial growth factor (VEGF), 
platelet-derived (PDGF) etc.]. Intracellular domain of this protein has a catalytic activity. 
Key tyrosine kinases responsible for the pathogenesis of malignancy are associated with: 
vascular endothelial factor, FLT-1 and FLT-3-like tyrosine kinase fms, KDR kinase insert 
domain-containing receptor and for platelet-derived growth factor, stem cell factor receptor 
and RET-protonkogen. The emergence of the cancer cells will result from mutation and 
constant activation of these receptors. 
Tyrosine kinase inhibitors block the activity of individual cells pathway-receptor signal 
transmission from membrane through cytoplasm to nucleus. They inhibit the activity of 
transcription factors and the expression of proteins responsible for fundamental processes of 
cancer cell development. 
3.1.1 Sunitinib (SU 011248) 
3.1.1.1 Mechanism of antitumor action of sunitinib 
Sunitinib is an oral antiangiogenic small molekule tyrosine kinase inhibitor. It inhibits 
VEGFR-1 to VEGFR-3, stem cell factor receptor, platelet-derived growth factor receptor 
PDGFR-2-alfa and PDGFR-beta, RET, colony-stimulating factor-1 receptor, and fetal liver 
tyrosine kinase receptor 3 FLT-3. [55] 
3.1.1.2 Clinical application of sunitinib 
Sunitinib was approved by the European Medicines Agency (EMEA) for the treatment of 
advanced kidney cancer and / or metastatic kidney cancer and for the treatment of 
unresectable and / or metastatic GIST after failure of imatinib treatment due to resistance to 
imatinib or intolerant. [56]  
3.1.1.3 Mechanism of cardiotoxicity of  sunitinb 
Sunitinib causes hypertension. In phase I clinical trials the incidence of CTC grade >=3 
hypertension was 7.3%. [57] In single-agent phase II clinical trials with sunitinib the rates of 
grade 1-2 and grade 3 hypertension were 8.4% and 7.5% respectively. [58] In phase III 
clinical trials which established the efficacy of sunitinib in gastrointestinal stroma tumors 
(GISTs) and renal cell carcinoma grade 3 hypertension was more frequent in the sunitinib 
group than in the placebo group (3% versus 0%) or the interferon group (8% versus 1%). 
[59,60]  
In phase I clinical trials of sunitinib two of 55 patients developed left ventricular 
dysfunction and heart failure. [57] In the phase II clinical trials of sunitinib in renal cell 
carcinoma 8.9% of patients developed a reduction in LVEF. [58] Grade 3 reductions in 
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LVEF were seen in a phase III trial of renal cell carcinoma. [60] In another retrospective 
analysis 11% of the patients with GISTs had heart failure and left ventricular dysfunction, 
18% of patients had a myocardial infarction and/or asymptomatic elevations in troponin. 
[61] At the University of Stanford among 48 patients treated with sunitinib within 22-435 
days after initiation of therapy in 7 (15%) patients experienced left ventricular III / IV 
grade according to the CTCAE (Common Terminology Criteria For Adverse Events). 
Despite the discontinuation of sunitinib heart failure maintained in 3 patients. Not 
without significance in this group of patients had a history of the burden from 
cardiovascular diseases as the 3 subjects had a history of heart failure, while another 2 
patients were burdened with coronary artery disease. [62] In the University of Texas at 
2.7% (6 / 224) of patients treated with sunitinib develop symptoms of heart failure during 
therapy in a one year. It is important that none of the reported patients prior to study 
entry had any heart disease. Five of the reported patients, who developed heart failure in 
the III and stage IV NYHA, required discontinuation of study drug. In one patient after 
the study drug dose reduction and after symptomatic treatment of heart failure symptoms 
subsided. [63] 
Only a few cases of thromboembolic complications were reported. In phase I trials 2 of 55 
patients developed myocardial infarction and pulmonary embolism. Two patients 
experienced pulmonary embolism and one experienced cerebrovascular accident in phase II 
studies. [57] These events were rare in phase III studies. [59,60]  
The mechanism of cardiotoxicity associated with sunitinib therapy is not entirely clear. 
There are various hypotheses on this subject. It is shown that sunitinib induces the 
development of hypertension. It is not confirmed, that this is the way of the development of 
cardiac systolic dysfunction. Sunitinib inhibits cardiac  PDGFR receptor. It is known that the 
number of active receptors and their signals transmitted to the interior have the great impact 
on survival of cardiomyocytes. Another hypothesis assumes that the mechanism of sunitinib 
cardiotoxicity may be related to inhibition of activating protein kinase (AMPK) and the 
kinase from the group of ribosomal S6 kinase (RSK 1). It is known that heart muscle cells 
require to function properly a large amount of energy. Thus they can be sensitive to 
inhibition of AMPK kinase, which acts as a regulating factor of the energy levels of ATP. 
Metformin used in diabetes, which activates AMPK kinase, does not protect against cardiac 
toxicity of treatment with sunitinib. [64] In addition, sunitinib treatment does not affect the 
level of cellular ATP. It is proven that the use of the dexrazoksan protection does not protect 
cardiomyocytes against the negative action of sunitinib. There are suggestions that the 
mechanism of toxicity of sunitinib is not associated with oxidative processes. Perhaps the 
non-selective inhibition of the kinase and blocking other pathways contribute to the 
development of drug-induced cardiotoxicity. [64] 
3.1.2 Sorafenib (BAY 439006) 
3.1.2.1 Mechanism of antitumor action of sorafenib 
Sorafenib is an oral small molecule tyrosine kinase inhibitor designed to inhibit C-type Raf 
kinase (c-RAF), FLT-3, KIT, and B-type Raf kinase (b-RAF), VEGFR-2, VEGFR-3 and PDGFR. 
[55] 
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3.1.2.2 Clinical application of sorafenib 
On the basis of multicenter clinical trials have shown that the use of sorafenib causes a 
statistically significant prolongation of progression-free survival of of patients with kidney 
cancer with prior ineffective immunotherapy. 
3.1.2.3 Mechanism of cardiotoxicity of  sorafenib 
It has been proven that sorafenib may increase the risk of acute coronary syndrome, 
including myocardial infarction. An independent review of two studies by the FDA 
indicated that the incidence of ischemia/infarction was higher in the sorafenib group (2.9%) 
than in the placebo group (0.4%). [65] In another study the incidences of cardiac ischemia 
and infarction was significantly higher in the sorafenib arm (3% versus <1%). [66] In 
addition, sorafenib therapy may contribute to the occurrence of hypertension as with other 
targeted therapies that inhibit angiogenesis. In single-agent and combination phase I clinical 
trials of sorafenib the incidence of grade 3-4 hypertension was 3%. [67] In phase II studies 
with sorafenib 12% of patients developed grade 1-2 and 13.8% developed grade 3 
hypertension. [68] In a phase III trial of sorafenib versus placebo in renal cell carcinoma 
hypertension was the most frequent serious adverse event but led to drug discontinuation in 
<1% of patients. The incidence of hypertension was significantly higher than in the placebo 
group: grade 2 10% versus 2% and grade 3-4 4% versus <1% , respectively. [66]  
Similarly in a phase III trial in hepatocellular carcinoma patients grade 3 hypertension was 
more frequent in the sorafenib arm, but the difference did not reach the level of statistical 
significance. [69] Sorafenib-associated thrombotic events were infrequent (phase I trials, 
grade 3 thrombotic events 0.8%). No grade 3-4 thromboembolic events were noted in single-
agent phase II studies or in phase III studies. [55] Perhaps the mechanism of cardiotoxicity 
of this drug results from inhibition of serine-threonine kinases RAF1 and BRAF. RAF1 
inhibition blocks the activity of apoptosis signal regulating kinase 1 (ASK1) and mammalian 
stearin kinase 2 (MST2), which are involved in the mechanisms of formation of oxidative 
stress associated with tissue damage. It is still unclear the blockade by the sorafenib RAF1 or 
its effect on the signal transmission pathway of RAF1 to ASK1 and MST2 is at fault. [64] 
3.1.3 Imatinib 
3.1.3.1 Mechanism of antitumor action of imatinib  
Imatinib strongly inhibits the tyrosine kinase Bcr-Abl, by blocking the transfer of a 
phosphate group from ATP molecules to the substrate protein tyrosine. Preventing this 
interaction blocks the ability to activate protein kinase transmitting proliferative signals to 
the nucleus and induces apoptosis of leukemia cells in patients with chronic myelogenous 
leukemia (CML) and acute lymphoblastic leukemia (ALL) with the Philadelphia 
chromosome. Imatinib also inhibits receptor tyrosine kinases platelet activation factor 
(PDGF), stem cell factor (SCF), Steel factor (c-KIT) and inhibits the cellular processes 
activated by PDGF and SCF. [70] 
3.1.3.2 Clinical application of imatinib 
This drug is used in the treatment of patient with chronic myelogenous leukemia and acute 
lymphoblastic leukemia. 
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3.1.3.3 Mechanism of cardiotoxicity of  imatinib 
O`Brief et al [71] reported ten individuals who developed severe congestive heart failure 
while on imatinib. They showed that imatinib-treated mice develop left ventricular 
contractile dysfunction. Transmission electron micrographs from humans and mice treated 
with imatinib showed mitochondrial abnormalities and accumulation of membrane whorls 
in both vacuoles and the sarco- (endo-) plasmic reticulum, findings suggestive of a toxic 
myopathy. With imatinib treatment, cardiomyocytes in culture show activation of the 
endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane 
potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell 
death. Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER 
stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of 
ER stress, largely rescues cardiomyocytes from imatinib-induced death. Thus, cardiotoxicity 
is an unanticipated side effect of inhibition of c-Abl by imatinib. [71] 
In turn, international and randomized phase III study involving 1106 patients with newly 
diagnosed chronic myeloid leukemia with Philadelphia chromosome, who are in chronic 
phase, severe cardiac failure and left ventricular dysfunction was reported in 0.7% of 
patients receiving imatinib, compared to 0,9% of patients treated with interferon alpha (IFN) 
with cytosine arabinoside (Ara-C). However, in the IRIS study, after imatinib treatment of 
heart failure incidence was 1% of patients. [72] 
Cardiac toxicity of imatinib may be due to inhibition by this drug tyrosine kinase c-Abl. It 
was confirmed that by the action of imatinib in response to oxidative stress occur: 
 activation of the endoplasmic reticulum (ER),  
 decreased mitochondrial membrane potential,  
 release of cytochrome c into the cytosol,  
 decrease in cell ATP and ultimately cell death. [71] 
3.1.4 Dasatinib 
3.1.4.1 Mechanism of antitumor action of dasatinib 
Dasatinib is a potent inhibitor of the tyrosine kinase Bcr-Abl. Also it blocks a number of 
other tyrosine kinases, including compounds belonging to the families: scr, c-kit and PDGFR 
eEPHA 2. 
3.1.4.2 Clinical application of dasatinib 
 This drug is used in the treatment of CML and Ph + ALL patients who had developed 
resistance to imatinib.  
3.1.4.3 Mechanism of cardiotoxicity of  dasatinib 
There have been reports of congestive heart failure and cardiac arrhythmias in patients 
during dasatinib therapy. This medicine may also cause QT prolongation. Treatment with 
dasatinib may increase the risk of pulmonary arterial hypertension. Patients who reported 
the occurrence of pulmonary hypertension during treatment with dasatinib usually received 
other cardiotoxic drugs or suffered from other chronic diseases. In these patients improved 
hemodynamic and clinical parameters after discontinuation of treatment dasatinib was 
reported. [73]  
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3.1.5 Lapatinib (GW572016) 
3.1.5.1 Mechanism of antitumor action of lapatinib 
Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of EGFR/ErbB1 
and HER2/ErbB2.  
3.1.5.2 Clinical application of lapatinib. 
This small molecule represents one of the most promising target therapies in breast cancer 
that overexpressed HER2. It is used in trastuzumab-refractory breast cancer. 
3.1.5.3 Mechanism of cardiotoxicity of  lapatinib 
Perez et al. reviewed the cardiotoxicity data of lapatinib in 3558 patients, including 1674 
breast cancer patients, already treated with the drug alone or in combination with other 
agents. A total of 1090 patients had >6 months exposure to lapatinib. Evaluation of cardiac 
left ventricular ejection fraction (LVEF) was done every 8 weeks while patients were 
receiving therapy, in addition to follow-up for any cardiac clinical events. A preliminary 
analysis of patients treated with lapatinib to date revealed that incidence of symptomatic  
 
 Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of several 
malignancies, converting lethal diseases into manageable, if not curable, chronic 
diseases. This is essential to limit toxicities of these agents. 
 The goal of tumor-cell killing by TKIs must be balanced against cardiotoxicity, 
because in some instances tumor cell death and preservation of cardiomyocyte health 
may be mutually exclusive. 
 Cardiomyocytes are contractile and have an extremely high demand for ATP. As a 
result, they might be particularly susceptible to agents that perturb mitochondrial 
function, either as a primary or secondary effect. Therefore, alterations in 
mitochondrial function could have a role in the cardiotoxicities of some currently 
approved agents.  
 Very few clinical trials have examined cardiotoxicities of TKIs in a prospective 
fashion with predefined cardiac endpoints, including left ventricular function. 
Therefore, there is a wide gap in our knowledge regarding the types, and risk of, 
cardiotoxicity for most of these agents.  
 Some current kinase targets in cancer are not expressed in cardiomyocytes. Therefore 
have little or no direct role in cardiomyocyte survival. The current generation of TKIs 
is inherently non-selective, and the purposeful design of multitargeted TKIs might 
allow a single agent to be more effective, and to be used in more types of cancer, but 
with this comes an increased risk of cardiotoxicity. In some cases this will probably 
be due to inhibition of ‘bystander’ targets that are not essential for the killing of 
tumour cells but that are involved in cardiomyocyte survival.  
 Identification of the kinase responsible for cardiotoxicity of an agent is important for 
future drug design. Future kinases should avoid this kinase. Thus, greater selectivity 
of individual agents may require the use of more agents to treat a particular cancer, 
but cardiotoxicity as an ‘off-target’ effect should be minimized.
Table 4. Tyrosine kinase inhibitors- SUMMARY  
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and asymptomatic decreased LVEF among 1674 breast cancer patients was 1.3% and was 
also 1.3% among 1453 patients with non- breast malignancies. Lapatinib- associated LVEF 
decrease was symptomatic in 0.1%, generally reversible/nonprogressive. Average duration of 
LVEF decrease was 40 days. The other studies conducted so far showed that the 
cardiotoxicity associated with lapatinib is not severe, is reversible, and usually patients can 
continue lapatinib therapy, when symptomatic treatment has been started. [54] 
3.2 Bortezomib 
Recent case reports provide alarming signals that treatment with bortezomib might be 
associated with cardiac events. 
3.2.1 Mechanism of antitumor action of bortezomib 
Bortezomib is a reversible proteasome inhibitor.  
3.2.2 Clinical application of bortezomib 
It is used in treatment of patients suffering from multiple myeloma or mantle cell lymphoma. 
3.2.3 Mechanism of cardiotoxicity of bortezomib 
Nowis et al. [74] reported that bortezomib treatment leads to left ventricular contractile 
dysfunction in rats manifested by a significant drop in left ventricle ejection fraction. It is 
important that in this study rats were not treated with other drugs. Dramatic ultrastructular 
abnormalities of cardiomyocytes, especially within mitochondria, were accompanied by 
decreased ATP synthesis and decreased cardiomyocyte contractility. [74] Bortezomib 
induced cardiac effects seem to be reversible. The risk of cardiotoxicity after bortezomib is 
higher in patients which have previously cardiac problems or being concomitantly treated 
with other chemotherapeutics including cardiotoxic anthracyclines. In a recent phase III 
clinical study of bortezomib was used in combination with pegylated liposomal 
doxorubicin, LVEF ejection fraction was reported to decrease in 7% of patients treated with 
bortezomib. [75] In another clinical study, grade 3 to 4 cardiac heart failure was reported in 
2 cases (one fatal) receiving bortezomib in combination with doxorubicin. [76]  
3.3 Monoclonal antibodies directed against the receptor or tyrosine kinase ligands 
3.3.1 Trastuzumab 
3.3.1.1 Mechanism of antitumor action of trastuzumab  
Trastuzumab is a monoclonal antibody selectively connecting to the extracellular domain of 
HER-2 receptor, which belongs to the family of epidermal growth factor receptors. 
Overexpression of this receptor is found in approximately 20-25% of breast cancers. It is 
presence is associated with poor prognosis and shorter overall survival time. [22]  
3.3.1.2 Clinical application of trastuzumab 
Trastuzumab improves response rate and survival in women with metastatic breast cancer 
with known overexpression of the HER-2 receptor. Also the use of trastuzumab 
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concurrently with adjuvant chemotherapy significantly improves the relapse-free survival 
and overall survival in women with overexpressing HER-2 receptor in localized form of 
breast cancer. [22]  
3.3.1.3 Risk factors for cardiotoxicity after treatment with trastuzumab  
The risk factors associated with trastuzumab cardiotoxicity include:  
 history of hypertension,  
 diabetes,  
 obesity,  
 older age,  
 past radiotherapy prior therapy with anthracyclines.  
It was proven that the risk of cardiomyopathy after trastuzumab (as opposed to 
anthracycline antibiotics) does not depend on the total dose of drug. Contrast, cardiac 
dysfunction associated with trastuzumab therapy is completely reversible after 
discontinuation of the drug and after symptomatic treatment and leaves without residual 
effects in the structure of cardiac muscle. [77]  
3.3.1.4 Mechanism of cardiotoxicity of trastuzumab 
Cardiotoxicity associated with trastuzumab was analyzed only in the phase III trials, 
sporadic cases relate to assessment of phase II trials, because nobody knows whether this 
drug may cause clinically significant cardiac complications. No patients were monitored in 
terms of efficiency of the cardiovascular system during trastuzumab therapy. 
Cardiac complications, grade IV NYHA (New York Heart Association) was observed in 2% of 
patients treated with trastuzumab in the first line, in 4% of patients treated with trastuzumab 
because of resistance to previous treatment, in 2% of patients treated with concomitant 
paclitaxel and trastuzumab (compared to 1% of patients the group receiving paclitaxel alone) 
and in 16% of patients receiving chemotherapy: adriamycin with cyclophosphamide (AC) plus 
trastuzumab (compared to 4% in the group receiving chemotherapy alone AC). Symptoms of 
heart failure occurred in 75.5% of patients (83 in the group of 110 patients). In 79% of cases 
symptomatic treatment of heart failure has proved effective. [77] 
Based on 7 studies: phase II and III, Cardiac Review and Evaluation Committee (CREC) 
conducted a retrospective analysis of cardiac events associated with trastuzumab therapy. 
One analysis was based on international study 222 women who received trastuzumab in the 
second or third line treatment of metastatic breast cancer. Patients were previously treated 
with anthracyclines (94% women), taxanes (67% women), radiotherapy (71% women), 
hormonal therapy (57% women). Cardiac complications were seen  in 10 patients (4.7%), 
including 3 patients after treatment with trastuzumab. 9 patient out of all who develop 
complication (n=10) had been treated with anthracylines previously. Most of the cardiac 
complications in this study were clinically significant. There was one death following a 
ventricular arrhythmia, in a patient after previous treatment with anthracyclines with 
reduced baseline left ventricular ejection fraction. [78] 
Another study conducted by CREC concerned randomized, international phase III study 
comparing trastuzumab in combination with chemotherapy to chemotherapy alone in 469 
patients with metastatic breast cancer. The symptoms of cardiotoxicity were observed in 
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27% of patients who received trastuzumab with anthracyclines and cyclophosphamide 
compared to 8% of patients after treatment with chemotherapy alone (anthracycline and 
cyclophosphamide without trastuzumab). In 13% of patients treated with paclitaxel with 
trastuzumab cardiac complications occurred. Continuation of trastuzumab did not affect the 
severity of dysfunction of the cardiovascular system in most patients. The symptomatic 
treatment was effective. [78] 
Further analysis concerned three trials [338 patients] where trastuzumab monotherapy was 
used. It was estimated that the risk of cardiotoxicity associated with trastuzumab was 4%. 
3% of patients had grade 3 and 4 toxicity according to Common Toxicity Criteria (CTC). [78] 
Mechanism of cardiotoxicity induced by trastuzumab is still not fully clear. But role of 
inhibition of normal cardiac repair pathways by this drug seem to be probable. Her-2 
heterodimerizes to Her-4, leading to autophosphorylation of the Her-2 tyrosine kinase 
domain. [79] This complex, which is the antitumor target of trastuzumab, is also active in 
cardiac repair. The complex is activated by neuregulin 1, which is secreted in paracrine 
fashion by cardiac endothelial cells that are under stress. [79] Activation of the complex 
leads to multiple downstream effects. In turn they lead to hypertrophy of cardiac myocytes 
in vivo. In mice, deletion of Her-2 results in a dilated cardiomyopathy. [80] Chien proposed 
a model in which various types of cardiac stress such as mechanical strain, anthracyclines, 
or hypoxia trigger two competing pathways of cardiac myocyte survival (mediated by 
neuregulin-1 or gp 130 cytokines) or apoptosis. The clinical outcome depends on which 
process prevails. In this model, treatment with trastuzumab blocks the survival pathway by 
preventing Her-2/Her-4 heterodimerization, thus shifting the balance to apoptosis. The 
result is decreased cardiac contractility and CHF. [81] 
Mechanism for inducing cardiotoxicity by trastuzumab is presented in Table nr 5.  
 
 by the presence of HER-2 receptor on cardiomyocytes, 
 blocks the cardiac survival pathway by preventing Her-2/Her-4 heterodimerization, 
  induced apoptosis of cardiomyocytes, 
 cased hypertrophy of cardiac myocytes, 
Table 5. Mechanism of cardiotoxicity of trastuzumab 
3.3.2 Bevacizumab 
3.3.2.1 Mechanism of antitumor action of bevacizumab 
Bevacizumab is a recombinant humanised IgG monoclonal antibody specifically binds to 
vascular endothelial growth factor (VEGF) and blocking its connection to the membrane 
receptor and thereby inhibits the process of neoangiogenesis.  
3.3.2.2 Clinical application of bevacizumab 
Bevacizumab is adjunct to cytotoxic drug combination. It is approved for use in colon, lung, 
renal and breast cancer. 
3.3.2.3 Mechanism of cardiotoxicity of bevacizumab  
Based on the research phase I and II found that the possible side effects of bevacizumab are:  
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 bleeding,  
 thromboembolism,  
 proteinuria,  
 hypertension.  
The presence of hypertension was reported in 5-7% of patients participating in clinical trials. It 
was also observed [in rare cases] development of encephalopathy associated with 
hypertension and subarachnoid haemorrhage. Patients after treatment with anthracyclines and 
radiotherapy are at increased risk for cardiac complications during or after treatment with 
bevacizumab. In patients previously treated with anthracyclines followed by mediastinal 
radiotherapy, the incidence of left heart failure was about 4%. When anthracyclines and 
radiotherapy were used at the same time heart failure was observed in 14% of patients. [54] 
In a randomized study breast cancer patients receiving paclitaxel with bevacizumab compared 
to patients receiving paclitaxel alone the risk of hypertension 3 and 4 level rose to about 15%, 
thromboembolic events up to about 2.5%, proteinuria to about 3.1% and cardiac function the 
left ventricle to 1.4%. One patient receiving bevacizumab with paclitaxel died of a myocardial 
infarction. [54] 
4. Cardiotoxicity of anagrelide 
1. Mechanism of antitumor action of anagrelide. 
Anagrelide works by inhibiting the maturation of platelets from megakaryocytes. The exact 
mechanism of action is unclear, although it is known to be a phosphodiesterase inhibitor. It 
is a potent inhibitor of phosphodiesterase-II. It inhibits PDE-3 and phospholipase A2.  
2. Clinical application of anagrelide. 
This medicine is a standard treatment of thrombocythemia in chronic myeloproliferative 
disorders: essential thrombocythaemia (ET), polycythemia vera (PV) and bone marrow 
fibrosis.  
3. The mechanism of cardiotoxicity of anagrelide. 
The mechanism of cardiotoxicity of this drug is not fully known. It may be due to medicine`s 
positive inotropic effect or consequence of vasodilatation and tachyarrhythmia induced by 
anagrelide. During the treatment following can occur: palpitations and tachycardia, less 
common- congestive heart failure, hypertension, arrhythmia, atrial fibrillation and the 
occasional- angina, myocardial infarction, cardiomegaly, cardiomyopathy, pericardial 
effusion, and orthostatic hypotension. [82] 
Anagrelide was found as a cause of cardiomyopathy in 2000 at the Mayo Clinic [Rochester, 
USA]. The data were collected from 434 patients suffered from essential thrombocythaemia 
and polycythemia vera. Investigators confirmed by echocardiography the development of 
idiopathic cardiomyopathy during treatment of these chronic myeloproliferative disorders 
with anagrelide in 11 patients. The decrease in LVEF was significant from 35% (two persons) 
to 10% (one person). Discontinuation of treatment with anagrelide resulted in an increased 
LVEF. [82] 
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Cardiotoxicity of anagrelide also confirmed case of 50-year-old man diagnosed with 
essential thrombocythaemia. Due to the increasing resistance to first-line treatment the 
patient was treated with anagrelide in a dose gradually increasing up to 2.5 mg twice a day. 
The patient developed clinical features of congestive heart failure, NYHA IV. LVEF was 
18%. ECG findings were typical for myocardial ischemia but troponin T level was normal. 
Coronary angiography was performed revealing normal in which the coronary arteries. 
Treatment of anagrelide was stopped, hydroxyurea therapy was started again. Patients 
received symptomatic therapy of heart failure: diuretics and ACE-inhibitors with good 
response. Hydroxyurea therapy once again proved to be ineffective. Doctors were decided 
to join hydroxyurea of anagrelide at a reduced dose 0.5 mg twice a day. Modification of 
treatment was effective, the level of platelets decreased to the normal limits, the symptoms 
of heart failure was absent. ECHO, made by 2 and 8 months after starting treatment with 
anagrelide [low doses] and hydroxyurea, showed increasing LVEF from 40 to 50%. [83] 
These observations confirm that the use of anagrelide is not absolutely safe to the 
cardiovascular system. Cardiomyopathy, during anagrelide treatment is rare but clinically 
significant. Therefore, patients with a history of heart disease should be treated with 
anagrelide with caution, when potential benefits exceed risk of this kind therapy. [82,83] 
Mechanism of cardiotoxicity associated with the action of anagrelide is showen in Table nr 6. 
 
 by positive inotropic effects, 
 by vasodilatation,  
 by tachyarrythmias, 
Table 6. The mechanism of cardiotoxicity of anagrelide 
5. Cardiotoxicity of High Dose Chemotherapy (HDC) followed by 
Hematopoietic Stem Cell Transplantation (HSCT) 
Hematopoietic stem cell transplantation (HSCT) has now become the treatment of choice for 
large number of malignant and non-malignant diseases. Cardiac complications may 
result from high-dose chemotherapy or irradiation administered during the 
conditioning phase of bone marrow and blood stem cell transplantation (BMT). Cardiac 
complications of high-dose cyclophosphamide and total body irradiation (TBI) or other 
intensive conditioning regimens administered prior to bone marrow and stem cell 
transplantation (BMT) have been well documented. Clinically, patients present with congestive 
heart failure and pancarditis. Hemorrhagic perimyocarditis with endothelial damage and 
microthrombi in capillaries as well as acute fibrinous pericarditis. Several other cytotoxic 
drugs such as busulfan, carmustine or cytarabine used in pre-BMT regimens may cause 
significant cardiotoxicity. Acute myocardial infarction and various cardiac arrhythmias 
including cardiac arrest as a consequence of infusion of cryopreserved marrow have been 
reported during the acute phase of BMT. Pretreatment with anti-tumor antibiotics 
including anthracyclines and prior mediastinal irradiation may increase the risks of 
adverse cardiac sequelae after BMT, but identification of the risk factors and effective 
strategies for cardiologic prescreening have not been well established. Although cardiac 
complications associated with BMT have been documented in several series, the incidence 
of reported cardiotoxicity has varied among investigators, probably reflecting patient 
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selection, differences in BMT preparative regimens and lack of universal grading system 
for cardiotoxic events. [84-87]  
Cardiac complications associated with exposure to the conditioning factors can be acute, 
with a relatively short or long period of latency after HSCT. [84-87] 
To assess the frequency of clinically serious cardiac toxicity related to the acute phase of 
bone marrow transplantation (BMT), investigators from University of Minnesota 
retrospectively examined life-threatening or fatal cardiotoxicity identified using the 
complications records of their transplant center clinical database. All serious cardiac toxicity 
events within 100 days of BMT except those attributable to septic shock, pneumonitis or 
multi-organ failure were reviewed. During the first 100 days after transplantation 628 
cardiac complications experienced and divided by four-level scale cardiac toxicity [86]: 
 Stage I- asymptomatic cardiomegaly, mild ECG changes, not requiring treatment, 
asymptomatic stroke in the pericardium, 
 Stage II- moderate changes in the ECG, which require and well respond to routine 
treatment, congestive heart failure responsive to afterload reduction in the treatment of 
diuretics and digitalis, pericarditis, 
 Stage III: severe abnormalities in the ECG with no or partial response to medical 
intervention, congestive heart failure, requiring drugs with isotropic, cardiogenic shock, 
reducing the voltage wave QRS&> 50%, pericardial tamponade. 
 Stage IV- death following cardiac toxicity. 
Of 2821 BMT patients at the University of Minnesota between 1977 and 1997, 26 were 
identified as having suffered major or fatal (n = 13) cardiotoxicity (0.9%, 19 adults and 
seven children). Rapidly progressive heart failure resulted in death of 11 patients, one 
patient had fatal pericardial tamponade, and one had an acute ventricular fibrillation 
arrest. The remaining 13 patients (50%) had life-threatening cardiotoxicity including 
four patients with pericardial tamponade and nine patients with cardiac 
arrhythmias. Overall, we observed that acute, major cardiotoxic events attributable to 
BMT are uncommon, occurring with a frequency of 1%. These data suggest that with 
appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and 
irradiation in the BMT preparative phase does not result in frequent, clinically relevant 
short-term cardiac toxicity. [86] 
The most common late complications of HSCT include valvular dysfunction, conduction 
disturbances, pericarditis and cardiomyopathies. Are also observed vascular complications, 
which include: coronary heart disease, cerebral vascular dysfunction and disease. [84-87] 
Investigators from City of Hope National Medical Center [87] examined the independent 
roles of pre-hematopoietic cell transplantation (HCT) therapeutic exposures, 
transplantation-related conditioning, and comorbidities (pre- and post-HCT) in the 
development of late congestive heart failure (CHF) after HCT. This was a nested case-control 
design. Individuals with late CHF (diagnosed 1 year after HCT) were identified from a cohort 
of 2,938 1 year survivors who underwent transplantation at City of Hope National Medical 
Center, Duarte, CA. This cohort formed the sampling frame for selecting controls (without 
CHF) matched for age and year of HCT, donor source (allogeneic v autologous), and length 
of follow-up. Sixty patients with late CHF were identified; median age at HCT was 45.3 
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years (range, 16.6 to 68.6 years); median time to CHF was 3.0 years (range, 1.03 to 18.9 
years); 68% received autologous HCT. Median ejection fraction was 36.9% (range, 15% to 
53%). Compared with matched controls (n = 166), patients with late CHF received more 
cycles of pre-HCT chemotherapy (8.6 v 4.9 cycles; P= 0.01), had greater body mass index at 
HCT (28.4 v 26.2 kg/m2; P= 0.01), greater lifetime anthracycline exposure (285.3 v 175.6 
mg/m2; P= 0.01), and were more likely to have multiple chronic comorbidities (30.0% v 
13.9%; P= 0.01). Multivariable analysis revealed number of pre-HCT chemotherapy cycles 
(odds ratio [OR] 1.2; P= 0.01), anthracycline dose 250 mg/m2 (OR 3.2; P= 0.05), and two or 
more chronic comorbidities (OR 4.3; P= 0.01) to be independently associated with late CHF. 
Pre-HCT exposure to anthracyclines and presence of comorbidities are primarily risk 
associated with late CHF after HCT. Conditioning-related therapeutic exposure does not 
contribute significantly to the risk. These results form the basis for identifying high-risk 
individuals for targeted surveillance, as well as developing preventive strategies in the 
form of aggressive management of comorbidities. [87] 
Considering all of the above the important factors affecting the occurrence of cardiotoxic 
high dose chemotherapy complications include exposure to high doses of 
cyclophosphamide, total body irradiation, prior anthracycline therapy, the presence of 
dimethyl sulfoxide (DMSO) in intravenous products, infectious complications associated 
with neutropenia. The risk of cardiac complications after HSCT is also influenced by patient 
age, type of therapy applied and previous medical history. [84] 
Dimethyl sulphoxide (DMSO) is cells protective factor, preventing the crystallization of 
water and damage to cell membranes collected stem cells, which are subjected to freezing in 
liquid nitrogen at temperatures below -120 degrees C. Cardiotoxicity associated with DMSO 
may result in hypotension, requiring fluid infusion or even inotropic drugs. Ones also 
reported cardiac arrhythmias such as atrial fibrillation, or bradycardia, and incidents of 
acute coronary syndromes. Cardiotoxicity associated with DMSO is rare. Wether DMSO is 
responsible for these has been questioned. [84,85]  Recent reports of similar acute cardiac 
events despite DMSO depletion have led to the suggestion that perhaps the complications 
seen following infusion may be more a product of the amount of infused granulocytes, 
rather than DMSO. [84]  
Infectious complications during early post-transplant neutropenia or prolonged 
immunosuppression for GVHD prophylaxis are common problems following HSCT. 
Overwhelming sepsis can lead to cardiopulmonary failure, necessitating prolonged 
intubation and cardiac inotropic support, potentially causing subclinical cardiotoxicity or 
other end-organ compromise that may not be evident until years following HSCT. [84] 
The Tichellis study [84] provided preliminary evidence for an association between GVHD 
and the development of arterial disease. There are emerging data to suggest that chronic 
GVHD could play a role in the development of cardiovascular disease. Cardiac side effects 
of chronic GVHD, while rare, likely occur as a result of direct organ lymphocytic infiltration. 
Increased levels of circulating tumor necrosis factor alfa [TNF alfa] may impair muscle 
electrical activity and compromise myocardial contractility. Furthermore, increased 
amounts of inflammatory markers, such as TNF alfa and interleukin-6, could perpetuate 
endothelial injury, contributing to premature arterial events in long-term survivors after 
allogeneic HSCT. Treatment of GVHD is not without cardiovascular consequences. 
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Prolonged treatment with calcineurin inhibitors and steroids can lead to myocardial 
hypertrophy, as well as increase the likehood of cardiovascular disease risk factors such as 
hypertension, diabetes, and renal insufficiency. [84]  
6. Carditoxicity of radiotherapy 
In anticancer treatment, radiotherapy plays an important role. It can also damage the heart 
muscle. Due to the location of the heart in human body, mediastinal radiotherapy poses the 
highest risk of cardiac complications. This form of treatment is commonly used in 
lymphoma, breast, esophageal and lung cancers. In connection with the expected long 
period of survival of patients with Hodgkin lymphoma and breast cancer the risk of 
complications from cardiovascular diseases is the highest. The maximum potential safe dose 
of ionizing radiation on the heart area are as follows [88]:  
 approximately 60 Gy when 25% or less heart volume is irradiated,  
 about 45 Gy, while 65% of the volume of the heart is irradiated with a standard 
fractionation at 2 Gy per day.  
Early cardiac complication after radiation therapy is acute pericarditis, which usually occurs 
within a few weeks after treatment. The most common late effect of radiotherapy on 
cardiovascular system is coronary artery disease. It usually appears within 10-15 years after 
radiation. Ones have been shown that ionizing radiation can initiate or accelerate the 
atherosclerotic process, this phenomenon refers mainly to people with other risk factors for 
cardiovascular disease. On others cardiac structures radiotherapy also has a negative effect, 
but to a lesser extent. It may lead to development of restrictive cardiomyopathy, cardiac 
diastolic dysfunction, impaired contractile function [that occurs after mated treatment with 
anthracyclines], aortic stenosis, QT prolongation, persistent tachycardia [damage of 
autonomic nervous system]. [88] 
Risk factors for acute or chronic cardiac complications after radiation therapy include [88]: 
 irradiated volume of the heart (cardiac risk is proportional to the irradiated volume of 
the heart),  
 patient age (younger age at the time of exposure to ionizing radiation is a risk factor for 
vascular disease),  
 time of exposure (the majority of published reports that the need for a minimum of 10 
years to the risk of death from heart attack increased above 10%),  
 dose and technique of application of ionizing radiation (it is considered that the total 
radiation dose in the case of mediastinal radiotherapy, increasing the risk of 
cardiovascular disease is> 35-40 Gy, whereas a fractional dose> 2 Gy per day) and 
 prior chemotherapy (especially anthracycline-based regimens).  
7. Cardiotoxicity of antagonists of 5-HT3 receptor  
Potentially cardiotoxic drugs, inevitably associated with oncology therapy, are also 
antagonists of 5-HT3 receptor. Chemotherapy, especially given in high doses causes of 
nausea and vomiting, which are very burdensome for the patient with neoplastic disease. 
The mechanism of vomiting is the release of large amount of serotonin, stimulating 5-HT3 
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receptors located on nerve endings centripetal parasympathetic system. Parasympathetic 
system also innervates the heart muscle, which explains the cause of the cardiac 
complications associated with this class of drugs. [89]  
Results of the review of clinical trials with MEDLINE database from the period 1963-2002 
for cardiotoxicity antagonists 5-HT3 receptor were as follows [89-91]:  
 ECG changes (PR, QRS, QT, QTc, JT) were small, reversible, clinically insignificant and 
dependent on the selected group of patients,  
 ECG changes occurred most frequently between 1 and 2 hours after administration of 
dolasetron, ondansetron and granisetron and returned to normal within 24 hours, no 
evidence of acute, clinically significant cardiac complications. 
Based on these data it was concluded that the benefits of this class of drugs greatly outweigh 
their adverse effects on the cardiovascular system. [91]  
Considering the high risk of cardiac complications due to oncological treatment, it is 
important to establish standards of conduct with patients undergoing cancer therapy 
proven to cardiac toxicity.  
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